Swiss Biotech Day 2018, Basel

SynDermix presents for the first time its strategy and platform technologies at the Emerging Biotech Companies session at Swiss Biotech Day.



The management of SynDermix announced today that the Delegate of the Board and Chief Executive Officer, Mr Dieter Hemmer, will present the company strategy and technologies during the Emerging Biotech Companies session at Swiss Biotech Day 2018. The event, which is taking place in Basel today, is organised by the Swiss Biotech Association of which SynDermix is a member. “We are excited by the opportunity to unfold our strategy and development activities to a broad industry audience for the first time,” said Mr Hemmer. “Our three proprietary technologies (plant lectins, nitric oxide and vibration therapies) provide the scientific basis for a robust pipeline of biopharmaceuticals and medical devices in areas of high unmet medical need. Our most advanced compound and medical device will be in Phase III and confirmatory trials within the next year. In parallel, we drive a wellcare pipeline which is currently led by a high-end anti-ageing serum that is expected to enter the market by the end of 2018.” He concluded: “We look forward to establishing partnerships that will support process excellence in the development of our assets and, eventually, their commercialisation.”


About SynDermix AG
SynDermix AG is a Swiss developer of innovative health technologies funded by private investors. The Company focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.

SynDermix has built a diversified portfolio of innovative assets which correspond to three distinct proprietary technology platforms: smart medical devices based on digital acoustic modulation; drugs and medical devices based on a topical nitric oxide-releasing formulation; and drug candidates based on a recombinant plant lectin. Its business model is to a large extent virtual, driven by a strategy of in-licensing, outsourcing and out-licensing; the Company enters into strategic partnerships with third parties for the acquisition, development and commercialisation of a robust portfolio of assets with high innovation value and commercial potential. For more information please visit:


SynDermix Management AG
Julian Heinrich

+41 44 366 40 16